Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Endocr Relat Cancer. 2016 Nov 14;24(1):41–52. doi: 10.1530/ERC-16-0402

Figure 2. Kaplan-Meier analyses of the impacts of BRAF V600E, RAS or TERT promoter mutations or their coexistence on patient survival and disease recurrence-free survival of patients with papillary thyroid cancer (PTC) in the TCGA database.

Figure 2

A. Impacts of BRAF V600E or TERT promoter mutations or their coexistence on patient survival. B. Impacts of BRAF V600E or TERT promoter mutations or their coexistence on PTC recurrence-free survival. The analyses in A and B were performed with exclusion of the cases positive for RAS mutations. C. Impacts of RAS or TERT promoter mutations or their coexistence on patient survival. D. Impacts of RAS or TERT promoter mutations or their coexistence on PTC recurrence-free survival. The analyses in C and D were performed with exclusion of the cases positive for BRAF V600E mutation. E. Impacts of BRAF/RAS or TERT promoter mutations or their coexistence on patient survival. F. Impacts of BRAF/RAS or TERT promoter mutations or their coexistence on PTC recurrence-free survival. The analyses in E and F were performed on the whole cohort of PTC patients without genetic-based exclusion. The Log-rank P value in each panel represents the comparison among the four groups globally.